HC Wainwright Issues Negative Forecast for CRBP Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Investment analysts at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a report issued on Monday, March 9th. HC Wainwright analyst A. Maldonado now expects that the biopharmaceutical company will earn ($1.32) per share for the quarter, down from their prior forecast of ($1.31). The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q2 2026 earnings at ($1.40) EPS, Q3 2026 earnings at ($1.47) EPS, Q4 2026 earnings at ($1.55) EPS, FY2026 earnings at ($5.74) EPS, FY2027 earnings at ($6.69) EPS, FY2028 earnings at ($5.00) EPS and FY2029 earnings at ($3.27) EPS.

A number of other analysts have also recently issued reports on CRBP. Weiss Ratings reissued a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, January 21st. Jefferies Financial Group upgraded Corbus Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, February 18th. Royal Bank Of Canada dropped their price objective on Corbus Pharmaceuticals from $55.00 to $53.00 and set an “outperform” rating on the stock in a report on Thursday, November 13th. Finally, Oppenheimer raised their price objective on shares of Corbus Pharmaceuticals from $53.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Corbus Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $43.71.

Corbus Pharmaceuticals Stock Down 8.1%

Shares of NASDAQ:CRBP opened at $9.59 on Thursday. Corbus Pharmaceuticals has a 12-month low of $4.64 and a 12-month high of $20.56. The firm has a market capitalization of $170.13 million, a P/E ratio of -1.60 and a beta of 2.84. The firm has a fifty day moving average of $8.27 and a two-hundred day moving average of $10.53.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings data on Monday, March 9th. The biopharmaceutical company reported ($1.25) EPS for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.53.

Insider Activity at Corbus Pharmaceuticals

In related news, insider Dominic Smethurst sold 3,285 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $8.09, for a total value of $26,575.65. Following the transaction, the insider directly owned 95,887 shares of the company’s stock, valued at approximately $775,725.83. This trade represents a 3.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC acquired a new stake in shares of Corbus Pharmaceuticals in the first quarter worth $573,000. Marshall Wace LLP bought a new position in Corbus Pharmaceuticals in the 2nd quarter worth $137,000. Baker Avenue Asset Management LP acquired a new position in Corbus Pharmaceuticals during the 2nd quarter worth $138,000. Bank of America Corp DE lifted its position in Corbus Pharmaceuticals by 333.6% during the 2nd quarter. Bank of America Corp DE now owns 71,893 shares of the biopharmaceutical company’s stock worth $496,000 after acquiring an additional 55,314 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Corbus Pharmaceuticals in the third quarter valued at about $1,080,000. Institutional investors and hedge funds own 64.64% of the company’s stock.

Key Corbus Pharmaceuticals News

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer raised its price target sharply to $57, a very bullish signal that can attract buyers and momentum-focused funds; this upgrade helps explain some intraday buying interest despite weakness elsewhere. Oppenheimer Boosts Price Target
• Positive Sentiment: Coverage pieces highlighting a consensus analyst upside (mean targets implying ~318% upside) are fueling bullish expectations and may bring fresh speculative demand from investors chasing upside potential. How Much Upside is Left?
• Neutral Sentiment: General analyst commentary roundup (Medpace, Revolution Medicines, Corbus) provides context but no single actionable change; useful for sentiment but not a direct catalyst. Analysts Offer Insights
• Neutral Sentiment: Reported short-interest data is effectively zero/ambiguous (entries show 0 shares and NaN increases), indicating little reported short pressure — this is unlikely to be a major driver of price moves today. (Source: market data feed)
• Negative Sentiment: HC Wainwright cut multiple EPS estimates across 2026–2029 (Q1–Q4 2026 and FY2026–FY2029), widening expected losses and lowering near- and medium-term expectations; those revisions are a clear negative fundamental catalyst and likely pressured the stock. HC Wainwright Lowers Estimates

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.